Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A8LP
|
|||
| Former ID |
DNC000168
|
|||
| Drug Name |
AG2034
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H21N5O6S2
|
|||
| Canonical SMILES |
C1C(SC2=C(N1)N=C(NC2=O)N)CCC3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O
|
|||
| InChI |
1S/C18H21N5O6S2/c19-18-22-14-13(16(27)23-18)31-9(7-20-14)2-1-8-3-5-11(30-8)15(26)21-10(17(28)29)4-6-12(24)25/h3,5,9-10H,1-2,4,6-7H2,(H,21,26)(H,24,25)(H,28,29)(H4,19,20,22,23,27)/t9-,10-/m0/s1
|
|||
| InChIKey |
HHKAOUMVRGSKLS-UWVGGRQHSA-N
|
|||
| CAS Number |
CAS 177575-17-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | GAR transformylase (GART) | Target Info | Modulator | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks. Cancer Chemother Pharmacol. 2000;45(5):423-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.